Arbekacin: Difference between revisions

Latest revision as of 11:03, 15 February 2025

An aminoglycoside antibiotic used in the treatment of bacterial infections

Arbekacin[edit]

Arbekacin is an aminoglycoside antibiotic that is used primarily in the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is a semi-synthetic derivative of kanamycin, which is another aminoglycoside antibiotic.

Mechanism of action[edit]

Arbekacin works by binding to the bacterial ribosome, specifically the 30S subunit, and inhibiting protein synthesis. This action is bactericidal, meaning it kills the bacteria rather than merely inhibiting its growth. The binding of arbekacin to the ribosome interferes with the initiation complex of protein synthesis and causes misreading of mRNA, leading to the production of nonfunctional or toxic peptides.

Clinical use[edit]

Arbekacin is primarily used in the treatment of infections caused by resistant strains of bacteria, such as MRSA. It is often reserved for cases where other antibiotics are ineffective due to resistance. Arbekacin is administered intravenously, and its use is typically limited to hospital settings.

Side effects[edit]

As with other aminoglycosides, arbekacin can cause nephrotoxicity and ototoxicity. Nephrotoxicity refers to kidney damage, while ototoxicity refers to damage to the ear, which can result in hearing loss or balance issues. Monitoring of drug levels and kidney function is important during treatment to minimize these risks.

Pharmacokinetics[edit]

Arbekacin is not absorbed from the gastrointestinal tract, so it must be administered parenterally. It is distributed widely in the body and is excreted primarily by the kidneys. The half-life of arbekacin can be prolonged in patients with renal impairment, necessitating dose adjustments.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''Arbekacin''' is an [[aminoglycoside]] antibiotic developed in Japan for the treatment of infections caused by multi-resistant bacteria. It is particularly effective against [[methicillin-resistant Staphylococcus aureus]] (MRSA) and other gram-positive bacteria. Arbekacin was synthesized to overcome the resistance mechanisms that bacteria have developed against other aminoglycosides. It works by binding to the bacterial [[ribosome]], inhibiting protein synthesis and ultimately leading to bacterial cell death.
+{{Short description|An aminoglycoside antibiotic used in the treatment of bacterial infections}}
-==Mechanism of Action==
+==Arbekacin==
-Arbekacin inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. This binding interferes with the initiation complex between mRNA and the ribosome, causing misreading of mRNA. Consequently, incorrect amino acids are inserted into the polypeptide, leading to the production of nonfunctional or toxic peptides which contribute to the bactericidal effect of the drug.
+[[File:Arbekacin_structure.svg|thumb|right|Chemical structure of Arbekacin]]
+'''Arbekacin''' is an [[aminoglycoside]] [[antibiotic]] that is used primarily in the treatment of infections caused by [[Gram-positive bacteria]], including [[methicillin-resistant Staphylococcus aureus]] (MRSA). It is a semi-synthetic derivative of [[kanamycin]], which is another aminoglycoside antibiotic.
-==Pharmacokinetics==
+==Mechanism of action==
-The pharmacokinetics of arbekacin are characterized by its poor absorption from the gastrointestinal tract, necessitating administration by intravenous or intramuscular injection. Once administered, arbekacin is distributed widely in the body, including to the kidneys, lungs, and bones. It is excreted primarily through the kidneys, with a half-life that allows for once or twice daily dosing in most patients.
+Arbekacin works by binding to the bacterial [[ribosome]], specifically the 30S subunit, and inhibiting protein synthesis. This action is bactericidal, meaning it kills the bacteria rather than merely inhibiting its growth. The binding of arbekacin to the ribosome interferes with the initiation complex of protein synthesis and causes misreading of mRNA, leading to the production of nonfunctional or toxic peptides.
-==Clinical Uses==
+==Clinical use==
-Arbekacin is used primarily in the treatment of serious infections caused by aerobic gram-positive bacteria, including MRSA. It is often reserved for cases where other, more commonly used antibiotics are ineffective due to resistance. Infections treated with arbekacin include septicemia, respiratory tract infections, skin and soft tissue infections, and bone and joint infections.
+Arbekacin is primarily used in the treatment of infections caused by resistant strains of bacteria, such as MRSA. It is often reserved for cases where other antibiotics are ineffective due to resistance. Arbekacin is administered intravenously, and its use is typically limited to hospital settings.
-==Resistance==
+==Side effects==
-While arbekacin was developed to overcome resistance to other aminoglycosides, bacterial resistance to arbekacin can still develop through various mechanisms. These include the modification of the target ribosomal binding sites, enzymatic modification of the drug, and changes in membrane permeability that reduce drug uptake. Continuous monitoring of bacterial susceptibility is necessary to ensure the continued efficacy of arbekacin in clinical practice.
+As with other aminoglycosides, arbekacin can cause [[nephrotoxicity]] and [[ototoxicity]]. Nephrotoxicity refers to kidney damage, while ototoxicity refers to damage to the ear, which can result in hearing loss or balance issues. Monitoring of drug levels and kidney function is important during treatment to minimize these risks.
-==Side Effects==
+==Pharmacokinetics==
-As with other aminoglycosides, arbekacin's use is associated with nephrotoxicity and ototoxicity. Nephrotoxicity may manifest as acute kidney injury, which is usually reversible upon discontinuation of the drug. Ototoxicity can result in hearing loss or balance disturbances, which may be irreversible. The risk of toxicity increases with higher doses and prolonged therapy, underscoring the importance of therapeutic drug monitoring.
+Arbekacin is not absorbed from the gastrointestinal tract, so it must be administered parenterally. It is distributed widely in the body and is excreted primarily by the kidneys. The half-life of arbekacin can be prolonged in patients with renal impairment, necessitating dose adjustments.
-==Conclusion==
+==Related pages==
-Arbekacin represents an important option in the treatment of infections caused by multi-resistant bacteria, particularly MRSA. Its development reflects the ongoing need for new antibiotics capable of overcoming bacterial resistance mechanisms. However, the potential for nephrotoxicity and ototoxicity requires careful patient monitoring to minimize adverse effects.
+* [[Aminoglycoside]]
+* [[Antibiotic resistance]]
+* [[Methicillin-resistant Staphylococcus aureus]]
+* [[Kanamycin]]
+[[Category:Aminoglycoside antibiotics]]
 [[Category:Antibiotics]]
-[[Category:Aminoglycosides]]
-{{Pharmacology-stub}}
-{{medicine-stub}}